Redburn Atlantic analyst Issie Kirby upgraded Alcon (ALC) to Buy from Neutral with a price target of CHF 93, up from CHF 80. The firm views fiscal 2025 as a pivotal year for Alcon with multiple new launches. The surgical equipment and dry eye pharma launches are the most material, the analyst tells investors in a research note. It predicts Alcon’s organic growth will accelerate on launch momentum.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC: